Hansoh Pharma Reports Positive Phase III Results for Osteosarcoma Drug Ris-Rez

Hansoh Pharmaceutical Group, a GSK licensor, announced positive topline results from its Phase III ARTEMIS-011 trial in China. The study evaluated risvutatug rezetecan (Ris-Rez), an antibody-drug conjugate, for relapsed osteosarcoma. The trial met its primary endpoint, showing statistically significant and clinically meaningful improvements in progression-free survival and consistent benefits in overall survival compared to chemotherapy.